1 Min Read
Dec 14 (Reuters) - Hologic Inc
* Expects to update its financial guidance for fiscal 2017 after transaction closes
* Transaction has been approved by boards of directors of both companies.
* For fiscal 2017 co's share of blood screening business was forecast to contribute $240 million revenue, GAAP EPS of $0.19, and non-GAAP EPS of $0.34
* Hologic to divest blood screening business to partner Grifols for $1.85 billion Source text for Eikon: Further company coverage: